Federal health officials are warning an HIV drug comes with the risk of a rare, but potentially deadly liver disorder.
The Food and Drug Administration says it has received more than 40 reports of the disorder since Bristol-Myers Squibb's Videx was approved in 1991. Four patients died from bleeding or liver failure after developing the problem.
The issue arises when there is dangerously slow blood flow through the liver, which can cause veins in the esophagus to burst.
The FDA says it's keeping Videx on the market, because its benefits outweigh the risks. The drug prevents HIV from multiplying.
New labeling on Videx says patients should be monitored for early signs of the problem during routine medical visits.